Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $5,000	175 Pages	The Business Research Company	January, 2024	BRC18450646

Best Price Guarantee
Price	from $5,000
Length	175 Pages
Publisher	The Business Research Company
Published Date	January, 2024
SKU	BRC18450646

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024

Including: 1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital 2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy3) By End-User: Hospitals; Specialty Clinics; HomecareCovering: Pfizer Inc.; Abbvie Inc.; Novartis AG; Ausio Pharmaceuticals LLC; Teva Pharmaceutical Industries Ltd.

Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vasomotor menopausal symptoms (vms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Description:

Where is the largest and fastest growing market for vasomotor menopausal symptoms (vms) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasomotor menopausal symptoms (vms) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

Markets Covered:1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes

2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels

3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users

Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Novartis AG; Ausio Pharmaceuticals LLC; Teva Pharmaceutical Industries Ltd.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.

1. Executive Summary
2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Characteristics
3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends And Strategies
4. Vasomotor Menopausal Symptoms (VMS) Treatment Market - Macro Economic Scenario: 4.1. Impact Of High Inflation On The Market; 4.2. Ukraine-Russia War Impact On The Market; 4.3. COVID-19 Impact On The Market
5. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Size and Growth: 5.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Drivers and Restraints; 5.1.1. Drivers Of The Market; 5.1.2. Restraints Of The Market; 5.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion); 5.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)
6. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segmentation: 6.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes; 6.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels; 6.3. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; Hospitals; Specialty Clinics; Homecare; Other End-Users
7. Vasomotor Menopausal Symptoms (VMS) Treatment Market Regional And Country Analysis: 7.1. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 7.2. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market: 8.1. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies; 8.2. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 8.3. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 8.4. Asia-Pacific Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Vasomotor Menopausal Symptoms (VMS) Treatment Market: 9.1. China Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 9.2. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion; 9.3. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion; 9.4. China Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Vasomotor Menopausal Symptoms (VMS) Treatment Market: 10.1. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 10.2. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 10.3. India Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market: 11.1. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 11.2. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 11.3. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 11.4. Japan Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market: 12.1. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 12.2. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 12.3. Australia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market: 13.1. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 13.2. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 13.3. Indonesia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market: 14.1. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 14.2. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 14.3. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 14.4. South Korea Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market: 15.1. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 15.2. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 15.3. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 15.4. Western Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market: 16.1. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 16.2. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 16.3. UK Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market: 17.1. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 17.2. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 17.3. Germany Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Vasomotor Menopausal Symptoms (VMS) Treatment Market: 18.1. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 18.2. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 18.3. France Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market: 19.1. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 19.2. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 19.3. Italy Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market: 20.1. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 20.2. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 20.3. Spain Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market: 21.1. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 21.2. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 21.3. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 21.4. Eastern Europe Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market: 22.1. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 22.2. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 22.3. Russia Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market: 23.1. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 23.2. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 23.3. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 23.4. North America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market: 24.1. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 24.2. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 24.3. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 24.4. USA Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market: 25.1. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 25.2. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 25.3. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 25.4. Canada Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market: 26.1. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 26.2. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 26.3. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 26.4. South America Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market: 27.1. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 27.2. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 27.3. Brazil Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market: 28.1. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 28.2. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 28.3. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 28.4. Middle East Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market: 29.1. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market Overview; 29.2. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 29.3. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion; 29.4. Africa Vasomotor Menopausal Symptoms (VMS) Treatment Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape And Company Profiles: 30.1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Landscape; 30.2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Company Profiles; 30.2.1. Pfizer Inc.; 30.2.1.1. Overview; 30.2.1.2. Products and Services; 30.2.1.3. Strategy; 30.2.1.4. Financial Performance; 30.2.2. Abbvie Inc.; 30.2.2.1. Overview; 30.2.2.2. Products and Services; 30.2.2.3. Strategy; 30.2.2.4. Financial Performance; 30.2.3. Novartis AG; 30.2.3.1. Overview; 30.2.3.2. Products and Services; 30.2.3.3. Strategy; 30.2.3.4. Financial Performance; 30.2.4. Ausio Pharmaceuticals LLC; 30.2.4.1. Overview; 30.2.4.2. Products and Services; 30.2.4.3. Strategy; 30.2.4.4. Financial Performance; 30.2.5. Teva Pharmaceutical Industries Ltd.; 30.2.5.1. Overview; 30.2.5.2. Products and Services; 30.2.5.3. Strategy; 30.2.5.4. Financial Performance
31. Vasomotor Menopausal Symptoms (VMS) Treatment Market Other Major And Innovative Companies: 31.1. Mylan N.V.; 31.2. Sun Pharmaceutical Industries Ltd.; 31.3. Aurobindo Pharma Limited; 31.4. Kyowa Kirin Co. Ltd.; 31.5. Dr. Reddy's Laboratories Ltd.; 31.6. Alembic Pharmaceuticals Limited Inc.; 31.7. Apotex Inc.; 31.8. Hikma Pharmaceutical plc; 31.9. Endo Pharmaceuticals plc; 31.10. Amneal Pharmaceuticals LLC; 31.11. Mundipharma International Ltd.; 31.12. Lupin Limited; 31.13. Glenmark Pharmaceuticals Ltd.; 31.14. Hisamitsu Pharmaceutical Co. Inc.; 31.15. Zhejiang Huahai Pharmaceutical Co. Ltd.
32. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Benchmarking
33. Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market
35. Vasomotor Menopausal Symptoms (VMS) Treatment Market Future Outlook and Potential Analysis: 35.1 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Countries Offering Most New Opportunities; 35.2 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Segments Offering Most New Opportunities; 35.3 Vasomotor Menopausal Symptoms (VMS) Treatment Market In 2028 - Growth Strategies; 35.3.1 Market Trend Based Strategies; 35.3.2 Competitor Strategies
36. Appendix: 36.1. Abbreviations; 36.2. Currencies; 36.3. Historic And Forecast Inflation Rates; 36.4. Research Inquiries; 36.5. The Business Research Company; 36.6. Copyright And Disclaimer